Hormonal and Cancer Replacement: What Scientific Studies Say

 

The relationship between hormone replacement therapy (HRT) and the risk of cancer is one of the biggest concerns for anyone considering this treatment. What scientific studies say is complex and nuanced, and cannot be summarized in a simple statement of “causes cancer”.

 

An honest and detailed look reveals that the risk varies significantly depending on the type of cancer, the combination of hormones, the route of administration, the dosage, the duration of treatment and, crucially, the moment in which it begins.

 

 The Key Evidence of Scientific Studies

 

The debate about HRT and cancer is based mainly on large-scale studies:

 

 Women's Health Initiative (WHI): This was the largest and most rigorous clinical trial on HRT. Its initial results in 2002 generated alarm, as one arm of the study (estrogen plus progestin) was stopped prematurely after detecting a small increase in the risk of invasive breast cancer.

     Initial analysis: An increase in the risk of breast cancer with the use of combined therapy (estrogen plus progestin), but not with estrogen alone therapy (in women with hysterectomy).

     Further reinterpretation: More detailed analyzes of the WHI and more recent studies have demonstrated that the risk of breast cancer associated with HRT is very small and is related to long-term use and, above all, with combined therapy. The risk appears to be negligible in the first years of use and begins to increase after 5 years.

 

 Million Women Study (United Kingdom): This was a large observational study that analyzed more than a million women. Their hallmarks also showed an increased risk of breast cancer in women who used HRT, especially combined it. However, as it is an observational study, it cannot prove a cause and effect relationship.

 

From these studies and more recent investigations, a more nuanced and detailed vision has emerged about the relationship between HRT and the risk of cancer.

 

 Types of Cancer and Relationship with TRH (Detail by Type)

 

1. Breast Cancer

 

 Risk with Combination Therapy: The most solid evidence indicates that the risk of breast cancer is slightly higher in women taking combined estrogen and progestin therapy (the standard combination for women with a uterus).

     Magnitude of Risk: The absolute risk is small. For every 1,000 women who use combined therapy for 5 years, 4 additional cases of breast cancer are expected compared to those who do not use it.

     Reversibility: Studies demonstrate that the risk of breast cancer returns to basal risk levels within 2 to 5 years following the interruption of HRT.

 Risk with Solo Estrogen Therapy: In women who underwent a hysterectomy and used solo estrogen therapy, the studies did not find an increase in the risk of breast cancer. Of course, some experts suggest a possible slight reduction.

 

2. Uterine (Endometrial) Cancer

 

 Risk with Solo Estrogen Therapy: If a woman with a uterus uses solo estrogen therapy, the risk of uterine (endometrial) cancer increases significantly. Estrogen promotes the growth of the uterine lining, and without progesterone to counteract it, the risk of cancer is high.

 The Solution: This risk is eliminated completely when progesterone is administered together with estrogen (combined therapy), as progesterone protects the uterine lining. This is the reason why combined therapy is the standard for women who do not have a uterus.

 

3. Ovarian Cancer

 

 Details of the Risk: Some observational studies have suggested a small increase in the risk of ovarian cancer with HRT, but the evidence is not as conclusive as for breast cancer or the uterus. It is considered an area of active research.

 

4. Colorectal Cancer

 

 Hallazgo: An interesting data from the WHI is that combined estrogen and progestin therapy was associated with a reduction in the risk of colorectal cancer.

 

 Key Factors that Influence Risk according to Science

 

Studies have revealed that the risks of TRH are not equal for everyone and are strongly influenced by:

 

 The moment of initiation of treatment: This is a critical factor. The cardiovascular risk (clots, strokes) and breast cancer is lower in women who start HRT during perimenopause or shortly after menopause (before 60 years or within 10 years of menopause). This is known as “the wind of opportunity”.

 The Way of Administration: Transdermal estrogen therapy (patches, gels) is considered safer than oral therapy, as it does not pass through the liver. Transdermal estrogen does not appear to increase the risk of blood clots, which is a significant advantage.

 The Hormonal Combination: The combination of estrogen and progestin has a different risk profile than that of solo estrogen. Also, the type of progestin (micronized natural progesterone vs. synthetic progestins) can influence the risk of breast cancer. Micronized natural progesterone is generally considered an option with a more favorable safety profile.

 Duration and Dosage: Higher doses and longer use (more than 5 years) are associated with an increase in risk.

 Individual Risk Factors: The risk of a woman with a family history of breast cancer, obesity and smoking will be greater.

 

 Conclusion: A Personalized and Medical Approach

 

Scientific studies have provided us with a much clearer and more nuanced view of hormonal replacement and the risk of cancer. The current medical consensus in Spain, at a global level, is that for women with severe symptoms, the use of HRT is a safe and effective option, as long as it is personalized to their needs and risk factors.

 

The decision to use HRT must be the result of a detailed and honest conversation between the patient and their doctor. The healthcare professional will evaluate all risk factors (personal and family), symptoms and potential benefits to determine the most appropriate therapy, the lowest and most effective dose, and the optimal follow-up plan. The key is the careful balance of benefits and risks, adapted to each individual.

 

Disclaimer: The information provided in this document is for educational purposes and should not be considered as medical advice. Always consult a qualified health professional before making any decision about your treatment.

Hormonal and Cancer Replacement: What Scientific Studies Say